Cite
HARVARD Citation
Hanf, D. et al. (2021). Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3G623R Solvent-Front Mutation. JCO precision oncology. p. . [Online].